clinical trial · NCT07780656
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
Pulmonary Disease, Chronic ObstructiveGSK5784283PlaceboStandard of care
brief summary
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
started
Sep 11, 2026
primary completion
Jul 20, 2029
completion
Mar 15, 2030
last updated
Nov 12, 2026
official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol